FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...
In this PharmTech video feature, I highlight the week’s industry news in an easy-to-consume format. New roundups drop every ...
Marcio Temtem, vice president, Strategic Business Management, Hovione, addresses molecule complexity, speed, and ...
Regarding the industry's talent pipeline, Dr. de Miguel highlights the importance of education programs in the fields of science, technology, engineering, and mathematics (STEM) in building the ...
Over the past four decades, rare disease drug development has evolved from a scientific aspiration into a central pillar of biopharmaceutical innovation. Regulatory reforms, scientific breakthroughs, ...
ACG’s Shirwal site is the first pharmaceutical packaging site in the WEF Lighthouse Network, using digital tools to cut ...
Discover proven strategies and innovative technologies to streamline microbial development, from early studies to GMP readiness. Learn from industry experts how to boost productivity, overcome ...
Cellares is partnering with Stanford Medicine to automate gene-edited stem cell therapy for HIV and more than 19 rare diseases.
Nine recommendations for extending therapeutic indications reflect ongoing lifecycle management and utility expansion of ...
Priority Review was granted by FDA for the first line metastatic TNBC treatment. Datroway significantly improved survival ...
In this forward-looking whitepaper, Blue Mountain explores how agentic AI —autonomous, context-aware AI agents—could ...
Dr. Stacy Lindborg is president and CEO of IMUNON, a clinical-stage company in phase 3 development with a lead DNA-mediated immunotherapy for advanced ovarian cancer. Dr. Lindborg has worked in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results